164 related articles for article (PubMed ID: 12555018)
1. Pharmacological prevention of post-ERCP pancreatitis: which therapy is best?
Mariani A
JOP; 2003 Jan; 4(1):68-74. PubMed ID: 12555018
[TBL] [Abstract][Full Text] [Related]
2. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study.
Andriulli A; Caruso N; Quitadamo M; Forlano R; Leandro G; Spirito F; De Maio G
JOP; 2003 Jan; 4(1):41-8. PubMed ID: 12555015
[TBL] [Abstract][Full Text] [Related]
3. Preventing post-ERCP pancreatitis: where are we?
Testoni PA
JOP; 2003 Jan; 4(1):22-32. PubMed ID: 12555013
[TBL] [Abstract][Full Text] [Related]
4. Antisecretory agents for prevention of post-ERCP pancreatitis: rationale for use and clinical results.
Poon RT; Fan ST
JOP; 2003 Jan; 4(1):33-40. PubMed ID: 12555014
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials.
Rudin D; Kiss A; Wetz RV; Sottile VM
J Gastroenterol Hepatol; 2007 Jul; 22(7):977-83. PubMed ID: 17559376
[TBL] [Abstract][Full Text] [Related]
6. Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis.
Testoni PA; Mariani A; Masci E; Curioni S
Dig Liver Dis; 2006 Aug; 38(8):588-95. PubMed ID: 16731060
[TBL] [Abstract][Full Text] [Related]
7. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
Zheng M; Chen Y; Yang X; Li J; Zhang Y; Zeng Q
BMC Gastroenterol; 2007 Feb; 7():6. PubMed ID: 17295917
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Andriulli A; Leandro G; Federici T; Ippolito A; Forlano R; Iacobellis A; Annese V
Gastrointest Endosc; 2007 Apr; 65(4):624-32. PubMed ID: 17383459
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic octreotide administration does not prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials.
Bai Y; Gao J; Zou DW; Li ZS
Pancreas; 2008 Oct; 37(3):241-6. PubMed ID: 18815543
[TBL] [Abstract][Full Text] [Related]
10. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis.
Budzyńska A; Marek T; Nowak A; Kaczor R; Nowakowska-Dulawa E
Endoscopy; 2001 Sep; 33(9):766-72. PubMed ID: 11558030
[TBL] [Abstract][Full Text] [Related]
11. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial.
Lee KT; Lee DH; Yoo BM
Pancreas; 2008 Nov; 37(4):445-8. PubMed ID: 18953260
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.
Manes G; Ardizzone S; Lombardi G; Uomo G; Pieramico O; Porro GB
Gastrointest Endosc; 2007 Jun; 65(7):982-7. PubMed ID: 17531632
[TBL] [Abstract][Full Text] [Related]
13. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial.
Li ZS; Pan X; Zhang WJ; Gong B; Zhi FC; Guo XG; Li PM; Fan ZN; Sun WS; Shen YZ; Ma SR; Xie WF; Chen MH; Li YQ
Am J Gastroenterol; 2007 Jan; 102(1):46-51. PubMed ID: 17266687
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
Cheng CL; Sherman S; Watkins JL; Barnett J; Freeman M; Geenen J; Ryan M; Parker H; Frakes JT; Fogel EL; Silverman WB; Dua KS; Aliperti G; Yakshe P; Uzer M; Jones W; Goff J; Lazzell-Pannell L; Rashdan A; Temkit M; Lehman GA
Am J Gastroenterol; 2006 Jan; 101(1):139-47. PubMed ID: 16405547
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis.
Masci E; Cavallini G; Mariani A; Frulloni L; Testoni PA; Curioni S; Tittobello A; Uomo G; Costamagna G; Zambelli S; Macarri G; Innocenti P; Dragonetti C;
Am J Gastroenterol; 2003 Oct; 98(10):2182-6. PubMed ID: 14572565
[TBL] [Abstract][Full Text] [Related]
16. Glyceryl trinitrate for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Bai Y; Xu C; Yang X; Gao J; Zou DW; Li ZS
Endoscopy; 2009 Aug; 41(8):690-5. PubMed ID: 19670137
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis.
Das A; Singh P; Sivak MV; Chak A
Gastrointest Endosc; 2007 Jun; 65(7):960-8. PubMed ID: 17331513
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic corticosteroids do not prevent post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
Bai Y; Gao J; Shi X; Zou D; Li Z
Pancreatology; 2008; 8(4-5):504-9. PubMed ID: 18765955
[TBL] [Abstract][Full Text] [Related]
19. Indomethacin for post-ERCP pancreatitis prophylaxis: another attempt at the Holy Grail.
Wagh MS; Sherman S
Am J Gastroenterol; 2007 May; 102(5):984-6. PubMed ID: 17489783
[TBL] [Abstract][Full Text] [Related]
20. Post-ERCP pancreatitis.
Arata S; Takada T; Hirata K; Yoshida M; Mayumi T; Hirota M; Yokoe M; Hirota M; Kiriyama S; Sekimoto M; Amano H; Wada K; Kimura Y; Gabata T; Takeda K; Kataoka K; Ito T; Tanaka M
J Hepatobiliary Pancreat Sci; 2010 Jan; 17(1):70-8. PubMed ID: 20012323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
